SMi Source lesson Anticoagulation: Studies and Registries has the following microlearning topics
1. Introduction
2. Learning Objectives
3. Dabigatran Clinical Trials
4. RELY Study
5. RELY: Study Population Results
6. RELY Results: Primary Outcome Stroke or Systemic Embolism
7. RELY Results: Secondary Outcome Stroke
8. RELY Results: Other Outcomes
9. RELY Results: Primary Safety Outcome Major-Bleeding, Dabigatran vs. Warfarin
10. RELY-ABLE
11. RELY-ABLE Trial
12. RECOVER Trial
13. RECOVER: Study Population Results
14. RECOVER: Primary and Secondary Efficacy Results
15. RECOVER: Results Summary
16. REMEDY and RESONATE Trials
17. REDEEM Trial
18. REDEEM Trial: D-dimer Concentrations
19. Development Programs: RE-ALIGN Heart Valves
20. Dabigatran Clinical Trials: Summary
21. Knowledge Check: Patient Population in the RELY Trial
22. Knowledge Check: RELY Trial Outcomes
23. Knowledge Check: RELY-ABLE Conclusion
24. Knowledge Check: Patient Population of the RECOVER Trial
25. Knowledge Check: RECOVER Trial Conclusion
26. Knowledge Check: Venous Thromboembolism and Anticoagulation Therapy
27. Rivaroxaban Clinical Trials: Overview
28. ROCKET Atrial Fibrillation
29. ROCKET Atrial Fibrillation: Baseline Characteristics Results
30. ROCKET Atrial Fibrillation: Primary Efficacy Results
31. ROCKET Atrial Fibrillation: Primary Efficacy Events During Transition to Open-Label Therapy
32. ROCKET Atrial Fibrillation: Secondary Efficacy Outcomes
33. ROCKET Atrial Fibrillation: Results Summary
34. XANTUS Study
35. EINSTEIN-DVT Study
36. EINSTEIN-DVT: Baseline Characteristic Results
37. EINSTEIN-DVT: Primary Efficacy Results
38. EINSTEIN-DVT: Primary Efficacy Results Time Course
39. EINSTEIN-DVT: Safety Results
40. EINSTEIN-DVT: Net Clinical Benefit and Summary
41. EINSTEIN-PE Trial
42. EINSTEIN-PE: Baseline Characteristics Results
43. EINSTEIN-PE: Primary Efficacy Results
44. EINSTEIN-PE: Primary Efficacy Results Time Course
45. EINSTEIN-PE: Safety Results
46. EINSTEIN-PE: Net Clinical Benefit and Summary
47. EINSTEIN-EXT Study
48. XALIA Study
49. ATLAS-ACS2 Trial
50. X-PLORER Study
51. Development Programs: Rivaroxaban
52. Rivaroxaban Clinical Trials: Summary
53. Knowledge Check: ROCKET AF Study
54. Knowledge Check: ROCKET AF Study
55. Knowledge Check: EINSTEIN-DVT and EINSTEIN-PE
56. Knowledge Check: EINSTEIN-DVT and EINSTEIN-PE
57. Knowledge Check: EINSTEIN-DVT and EINSTEIN-PE
58. Knowledge Check: EINSTEIN-EXT Trial
59. Knowledge Check: ATLAS-ACS2 Trial
60. Apixaban Clinical Trials
61. AVERROES Study
62. ARISTOTLE Trial
63. ARISTOTLE: Baseline Characteristics Results
64. ARISTOTLE: Efficacy Results
65. ARISTOTLE: Safety Results
66. ARISTOTLE: Results Summary
67. AMPLIFY Study
68. AMPLIFY Study: Baseline Characteristics Results and Primary Efficacy Results
69. AMPLIFY Study: Safety Results
70. AMPLIFY Study: Results Summary
71. AMPLIFY-EXT Study
72. APPRAISE2 Trial
73. Development Programs: Overview
74. Apixaban Clinical Trials: Summary
75. Knowledge Check: AVERROES Trial
76. Knowledge Check: ARISTOTLE Trial - Apixaban vs. Warfarin
77. Knowledge Check: ARISTOTLE Trial - Apixaban
78. Knowledge Check: AMPLIFY Trial - Apixaban
79. Knowledge Check: AMPLIFY Trial - Apixaban vs. Conventional Therapy
80. Knowledge Check: AMPLIFY-EXT Trial
81. Knowledge Check: APPRAISE 2 Trial - Patient Population
82. Knowledge Check: APPRAISE 2 Trial - Conclusion
